Phencyclidine-induced loss of asymmetric spine synapses in rodent prefrontal cortex is reversed by acute and chronic treatment with olanzapine

Neuropsychopharmacology

Volumn 36, Issue 10, 2011, Pages 2054-2061

  Elsworth, John D ^a   Morrow, Bret A ^a   Hajszan, Tibor ^a,b   Leranth, Csaba ^a   Roth, Robert H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

asymmetric spine synapse; olanzapine; phencyclidine; prefrontal cortex; pyramidal cell; schizophrenia

Indexed keywords

DOPAMINE; OLANZAPINE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DENDRITIC SPINE; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SYNAPSE; SYNAPTIC INHIBITION;

ANIMALS; BENZODIAZEPINES; CELL COUNT; DENDRITIC SPINES; DRUG ADMINISTRATION SCHEDULE; MALE; NEURONAL PLASTICITY; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SYNAPSES; TREATMENT OUTCOME;

EID: 80051790747     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.96     Document Type: Article

References (67)

1. Abdul-Monim Z, Reynolds GP, Neill JC (2003). The atypical antipsychotic ziprasidone, but not haloperidol, improves phen-cyclidine-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol 17: 57-65. (Pubitemid 36373141)
2. Abdul-Monim Z, Reynolds GP, Neill JC (2006). The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 169: 263-273.
3. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR et al (1999). Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156: 1580-1589. (Pubitemid 29459991)
4. Aravagiri M, Teper Y, Marder SR (1999). Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20: 369-377. (Pubitemid 30449775)
5. Black JE, Kodish IM, Grossman AW, Klintsova AY, Orlovskaya D, Vostrikov V et al (2004). Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am J Psychiatry 161: 742-744. (Pubitemid 38445521)
6. Broadbelt K, Byne W, Jones LB (2002). Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex. Schizophr Res 58: 75-81. (Pubitemid 35287286)
7. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS (1979). Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205: 929-932. (Pubitemid 10243358)
8. Buckley PF, Mahadik S, Pillai A, Terry Jr A (2007). Neurotrophins and schizophrenia. Schizophr Res 94: 1-11. (Pubitemid 47033973)
9. Carvalho AL, Caldeira MV, Santos SD, Duarte CB (2008). Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol 153(Suppl 1): S310-S324. (Pubitemid 351340985)
10. Chay SH, Herman JL (1998). [Disposition of the novel anti-schizophrenic drug [14C]olanzapine in male Fischer 344 and female CD rats following single oral dose administration]. Arzneimittelforschung 48: 446-454. (Pubitemid 28247629)
11. Cosgrove J, Newell TG (1991). Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol 47: 159-169.
12. Cronenwett WJ, Csernansky J (2010). Thalamic pathology in schizophrenia. Curr Top Behav Neurosci 4: 509-528.
13. Czubak A, Nowakowska E, Kus K, Burda K, Metelska J, Baer-Dubowska W et al (2009). Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacol Rep 61: 1017-1023.
14. Dazzi L, Seu E, Cherchi G, Biggio G (2004). Inhibition of stress-induced dopamine output in the rat prefrontal cortex by chronic treatment with olanzapine. Biol Psychiatry 55: 477-483. (Pubitemid 38338535)
15. Durany N, Michel T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P et al (2001). Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 52: 79-86. (Pubitemid 32947050)
16. Eccles J (1964). The Physiology of Synapses. Springer-Verlag: Heidelberg.
17. Freedman R (2003). Schizophrenia. N Engl J Med 349: 1738-1749. (Pubitemid 37315012)
18. Fumagalli F, Racagni G, Colombo E, Riva MA (2003). BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice. Mol Psychiatry 8: 898-899.
19. Fuster JM (1997). The Prefrontal Cortex: Anatomy, Physiology, and Neuropsychology of the Frontal Lobe. Lippincott-Raven: Philadelphia.
20. Gabbott PL, Dickie BG, Vaid RR, Headlam AJ, Bacon SJ (1997). Local-circuit neurones in the medial prefrontal cortex (areas 25, 32 and 24b) in the rat: morphology and quantitative distribution. J Comp Neurol 377: 465-499. (Pubitemid 27053544)
21. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM et al (1998). Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry 65: 446-453. (Pubitemid 28438871)
22. Glantz LA, Lewis DA (2000). Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57: 65-73. (Pubitemid 30035660)
23. Goldman-Rakic PS, Leranth C, Williams SM, Mons N, Geffard M (1989). Dopamine synaptic complex with pyramidal neurons in primate cerebral cortex. Proc Natl Acad Sci USA 86: 9015-9019. (Pubitemid 20010358)
24. Gottmann K, Mittmann T, Lessmann V (2009). BDNF signaling in the formation, maturation and plasticity of glutamatergic and GABAergic synapses. Exp Brain Res 199: 203-234.
25. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ (2010). Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry, e-pub ahead of print 24 August 2010; doi:10.1038/mp.2010.88 (in press).
26. Hajszan T, Leranth C, Roth RH (2006). Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol Psychiatry 60: 639-644. (Pubitemid 44402369)
27. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN et al (2005). Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25: 372-383. (Pubitemid 40105607)
28. Hof PR, Morrison JH (2004). The aging brain: morphomolecular senescence of cortical circuits. Trends Neurosci 27: 607-613. (Pubitemid 39221397)
29. Issa G, Wilson C, Terry Jr AV, Pillai A (2010). An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. Neurobiol Dis 39: 327-333.
30. Jentsch JD (1999). Neurochemical substrates of cognitive dysfunction produced by the psychotomimetic drug phencyclidine. Ph.D. thesis, Yale University, New Haven, CT.
31. Jentsch JD, Dazzi L, Chhatwal JP, Verrico CD, Roth RH (1998). Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats. Neurosci Lett 258: 175-178. (Pubitemid 29023576)
32. Jentsch JD, Redmond Jr DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997a). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277: 953-955. (Pubitemid 27366680)
33. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmaco-logy 20: 201-225. (Pubitemid 29067401)
34. Jentsch JD, Roth RH (2000). Effects of antipsychotic drugs on dopamine release and metabolism in the central nervous system. In: Lidow L (ed). Neurotransmitter Receptors in Actions of Antipsychotic Medications. CRC Press: Boca Raton, Florida. pp 31-41.
35. Jentsch JD, Roth RH, Taylor JR (2000). Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action. Prog Brain Res 126: 433-453. (Pubitemid 35461304)
36. Jentsch JD, Shahid M, Wong EHF, Roth RH (2006). Asenapine improves cognition function in monkeys repeatedly exposed to the psychostimulant phencyclidine. Biol Psychiatry 59: 145S.
37. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH (1997b). Subchronic phencyclidine administration reduces mesoprefron-tal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17: 92-99.
38. Kalus P, Muller TJ, Zuschratter W, Senitz D (2000). The dendritic architecture of prefrontal pyramidal neurons in schizophrenic patients. Neuroreport 11: 3621-3625.
39. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM et al (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64: 633-647. (Pubitemid 46878665)
40. Kolluri N, Sun Z, Sampson AR, Lewis DA (2005). Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 162: 1200-1202. (Pubitemid 40770705)
41. Kuppers E, Beyer C (2001). Dopamine regulates brain-derived neurotrophic factor (BDNF) expression in cultured embryonic mouse striatal cells. Neuroreport 12: 1175-1179. (Pubitemid 32374739)
42. Kuroki T, Meltzer HY, Ichikawa J (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288: 774-781. (Pubitemid 29119694)
43. Li XM, Perry KW, Wong DT, Bymaster FP (1998). Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychophar-macology (Berl) 136: 153-161. (Pubitemid 28137955)
44. McLean SL, Neill JC, Idris NF, Marston HM, Wong EH, Shahid M (2010). Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behav Brain Res 214: 240-247.
45. Mizoguchi K, Yuzurihara M, Ishige A, Sasaki H, Chui DH, Tabira T (2000). Chronic stress induces impairment of spatial working memory because of prefrontal dopaminergic dysfunction. J Neurosci 20: 1568-1574. (Pubitemid 30220435)
46. Nimchinsky EA, Sabatini BL, Svoboda K (2002). Structure and function of dendritic spines. Annu Rev Physiol 64: 313-353. (Pubitemid 34259233)
47. Perez-Costas E, Guidetti P, Melendez-Ferro M, Kelley JJ, Roberts RC (2008). Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays. J Neural Transm 115: 745-753.
48. Perry PJ, Sanger T, Beasley C (1997). Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 17: 472-477. (Pubitemid 28389187)
49. Peters A, Sethares C, Luebke JI (2008). Synapses are lost during aging in the primate prefrontal cortex. Neuroscience 152: 970-981.
50. Pillai A (2008). Decreased expression of Sprouty2 in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder: a correlation with BDNF expression. PLoS One 3: e1784.
51. Pioli EY, Meissner W, Sohr R, Gross CE, Bezard E, Bioulac BH (2008). Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats. Neuroscience 153: 1213-1224.
52. Poo MM (2001). Neurotrophins as synaptic modulators. Nat Rev Neurosci 2: 24-32.
53. Radley JJ, Rocher AB, Miller M, Janssen WG, Liston C, Hof PR et al (2006). Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb Cortex 16: 313-320. (Pubitemid 43209205)
54. Rotaru DC, Barrionuevo G, Sesack SR (2005). Mediodorsal thalamic afferents to layer III of the rat prefrontal cortex: synaptic relationships to subclasses of interneurons. J Comp Neurol 490: 220-238. (Pubitemid 41140990)
55. Sesack SR, Snyder CL, Lewis DA (1995). Axon terminals immunolabeled for dopamine or tyrosine hydroxylase synapse on GABA-immunoreactive dendrites in rat and monkey cortex. J Comp Neurol 363: 264-280.
56. Shoval G, Weizman A (2005). The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsy-chopharmacol 15: 319-329. (Pubitemid 40487736)
57. Silva AJ (2003). Molecular and cellular cognitive studies of the role of synaptic plasticity in memory. J Neurobiol 54: 224-237. (Pubitemid 36043676)
58. Smiley JF, Goldman-Rakic PS (1993). Heterogeneous targets of dopamine synapses in monkey prefrontal cortex demonstrated by serial section electron microscopy: a laminar analysis using the silver-enhanced diaminobenzidine sulfide (SEDS) immuno-labeling technique. Cereb Cortex 3: 223-238. (Pubitemid 23184930)
59. Sterio DC (1984). The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 134: 127-136. (Pubitemid 14121386)
60. Tamminga CA, Buchanan RW, Gold JM (1998). The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 13(Suppl 3): S21-S26. (Pubitemid 28282866)
61. Toni N, Buchs PA, Nikonenko I, Bron CR, Muller D (1999). LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite. Nature 402: 421-425. (Pubitemid 129544831)
62. Ueyama T, Kawai Y, Nemoto K, Sekimoto M, Tone S, Senba E (1997). Immobilization stress reduced the expression of neurotrophins and their receptors in the rat brain. Neurosci Res 28: 103-110. (Pubitemid 27267820)
63. Van Eden CG, Hoorneman EM, Buijs RM, Matthijssen MA, Geffard M, Uylings HB (1987). Immunocytochemical localization of dopamine in the prefrontal cortex of the rat at the light and electron microscopical level. Neuroscience 22: 849-862.
64. Wang CC, Shyu BC (2004). Differential projections from the mediodorsal and centrolateral thalamic nuclei to the frontal cortex in rats. Brain Res 995: 226-235.
65. Wang HD, Deutch AY (2008). Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsycho-tic drug treatment. Neuropsychopharmacology 33: 1276-1286. (Pubitemid 351521724)
66. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE (2003). Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 8: 592-610. (Pubitemid 36898018)
67. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsy-chopharmacol 8: 457-472. (Pubitemid 41002500)